Predictive biomarkers for immunotherapy in endometrial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective exploratory, translational study focused on identifying biomarkers that predict or prognosticate response to immunotherapy in endometrial cancer. Researchers will analyze paired fresh-frozen and FFPE tumor samples to integrate molecular and epigenetic data. The goal is to improve patient selection by uncovering factors beyond MMR status that influence treatment outcomes. The study is conducted at the European Institute of Oncology in Milan, in collaboration with MaNGO, and does not involve a standard randomized intervention beyond collecting and analyzing samples. Participants must be adults with advanced or recurrent disease who have not previously received immune checkpoint inhibitors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Histologically confirmed advanced or recurrent endometrial carcinoma or carcinosarcoma
* No prior treatment with immune checkpoint inhibitors
* Availability of paired fresh-frozen and FFPE tumor samples
* Provision of written informed consent for participation in translational research

Exclusion Criteria:

* Refusal or inability to provide informed consent by the patient or legal representative
* Mesenchymal tumors or epithelial tumors of non-endometrial origin (e.g., ovarian cancer)
* Active treatment with immunomodulatory agents at the time of sample collection (e.g., immunotherapy for autoimmune disease)
* Known positivity for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)

Where it's running

• European Institute of Oncology
  Milan, Italy, Italy Recruiting

Study contacts

• Principal investigator: Ilaria Betella — European Institute of Oncology
• Study coordinator: Ilaria Betella, MD
• Email: ilaria.betella@ieo.it
• Phone: +390257489431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized navigation to support rural and Black women with endometrial cancer

  This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07927244

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

• Liquid biopsy screening for early endometrial cancer in regional China

  A non-invasive blood test using cell-free DNA is being tested to see if it can detect early endometrial cancer and tell apart benign from malignant uterine lesions.

  Recruiting Guizhou Provincial People's Hospital · Guiyang, Guizhou · NCT07892755

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.